2 weeks Ago By ABMN Staff
Legal & General Group Plc reduced its position in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.
The firm owned 232,654 shares of the biotechnology company’s stock after selling 10,867 shares during the quarter. Legal & General Group Plc’s holdings in Iovance Biotherapeutics were worth $1,722,000 at the end of the most recent quarter. A number of other hedge funds also recently modified their holdings of the business.
AlphaQuest LLC lifted its stake in Iovance Biotherapeutics by 63.6% in the 4th quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 1,794 shares in the last quarter.
SBI Securities Co. Ltd. acquired a new position in shares of Iovance Biotherapeutics in the 4th quarter valued at about $36,000.
Impact Partnership Wealth LLC purchased a new stake in shares of Iovance Biotherapeutics in the fourth quarter worth approximately $83,000. Kazazian Asset Management LLC acquired a new stake in shares of Iovance Biotherapeutics during the fourth quarter worth approximately $84,000. Finally, Clear Creek Financial Management LLC purchased a new position in Iovance Biotherapeutics during the fourth quarter valued at approximately $91,000.
Hedge funds and other institutional investors own 77.03% of the company’s stock. Iovance Biotherapeutics Stock Performance IOVA opened at $3.
51 on Friday. Iovance Biotherapeutics, Inc. has a twelve month low of $2.
70 and a twelve month high of $14.23. The business has a 50 day moving average price of $3.
73 and a 200 day moving average price of $6.58. The firm has a market cap of $1.
15 billion, a P/E ratio of -2.36 and a beta of 1.05.
Analyst Ratings Changes A number of research firms have issued reports on IOVA. The Goldman Sachs Group decreased their target price on shares of Iovance Biotherapeutics from $18.00 to $16.
00 and set a “buy” rating for the company in a research note on Thursday, April 17th. Robert W. Baird lowered their target price on Iovance Biotherapeutics from $24.
00 to $20.00 and set an “outperform” rating on the stock in a research note on Friday, February 28th. Truist Financial cut their price target on Iovance Biotherapeutics from $25.
00 to $15.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $32.
00 price target on shares of Iovance Biotherapeutics in a research note on Friday, February 28th. Finally, Barclays cut their price objective on shares of Iovance Biotherapeutics from $22.00 to $5.
00 and set an “overweight” rating on the stock in a research report on Monday, April 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.
com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.22. View Our Latest Report on Iovance Biotherapeutics Iovance Biotherapeutics Profile ( Free Report ) Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. Read More Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics, Inc.
( NASDAQ:IOVA – Free Report ). Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
